Personalized drug testing in a patient with non-small-cell lung cancer using cultured cancer cells from pleural...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Non-small-cell lung cancer (NSCLC) patients with primary or acquired resistance to tyrosine kinase inhibitors (TKIs) exhibit poor response to targeted therapies.
• Liquid biopsies offer a less invasive alternative for obtaining cancer cells for analysis.

Purpose of the Study:

• To investigate the feasibility of culturing cancer cells from liquid biopsies of TKI-resistant NSCLC patients.
• To evaluate the potential of in vitro drug sensitivity testing to predict patient response to chemotherapy and targeted therapies.

Main Methods:

• Cancer cells were cultured from pleural effusion of a TKI-resistant NSCLC patient using a conditional reprogramming technique.
• Phenotypic drug sensitivity was assessed using the Cell Counting Kit-8 assay, evaluating individual drugs and combinations.

Main Results:

• In vitro drug sensitivity testing results, specifically for the combination of cisplatin and pemetrexed, correlated with the patient's clinical response.
• This study demonstrates the first successful predictive testing for combination therapy in EGFR-mutant NSCLC with primary TKI resistance.

Conclusions:

• This novel strategy of culturing cells from liquid biopsies and performing in vitro drug testing can predict treatment response in NSCLC patients with TKI resistance.
• The approach holds promise for improving clinical management of NSCLC patients, including those with acquired resistance or lacking targetable mutations, applicable to both chemotherapy and targeted therapies.